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Background-—Multiple scores have been proposed to stratify bleeding risk, but their value to guide dual antiplatelet therapy
duration has never been appraised. We compared the performance of the CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines), ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy), and HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke,
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) scores in 1946 patients recruited in the
Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) and assessed
hemorrhagic and ischemic events in the 24- and 6-month dual antiplatelet therapy groups.
Methods and Results-—Bleeding score performance was assessed with a Cox regression model and C statistics. Discriminative
and reclassiﬁcation power was assessed with net reclassiﬁcation improvement and integrated discrimination improvement. The C
statistic was similar between the CRUSADE score (area under the curve 0.71) and ACUITY (area under the curve 0.68), and higher
than HASBLED (area under the curve 0.63). CRUSADE, but not ACUITY, improved reclassiﬁcation (net reclassiﬁcation index 0.39,
P=0.005) and discrimination (integrated discrimination improvement index 0.0083, P=0.021) of major bleeding compared with
HAS-BLED. Major bleeding and transfusions were higher in the 24- versus 6-month dual antiplatelet therapy groups in patients with
a CRUSADE score >40 (hazard ratio for bleeding 2.69, P=0.035; hazard ratio for transfusions 4.65, P=0.009) but not in those with
CRUSADE score ≤40 (hazard ratio for bleeding 1.50, P=0.25; hazard ratio for transfusions 1.37, P=0.44), with positive interaction
(Pint=0.05 and Pint=0.01, respectively). The number of patients with high CRUSADE scores needed to treat for harm for major
bleeding and transfusion were 17 and 15, respectively, with 24-month rather than 6-month dual antiplatelet therapy; corresponding
ﬁgures in the overall population were 67 and 71, respectively.
Conclusions-—Our analysis suggests that the CRUSADE score predicts major bleeding similarly to ACUITY and better than HAS
BLED in an all-comer population with percutaneous coronary intervention and potentially identiﬁes patients at higher risk of
hemorrhagic complications when treated with a long-term dual antiplatelet therapy regimen.
Clinical Trial Registration-—URL: http://clinicaltrials.gov. Unique identiﬁer: NCT00611286. ( J Am Heart Assoc. 2015;4:
e002524 doi: 10.1161/JAHA.115.002524)
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B leeding is a common adverse event after percutaneouscoronary intervention and is associated with increased
morbidity and mortality.1–4 Bleeding predictors have been
described extensively; they are related mostly to the patient’s
clinical characteristics, the invasiveness of the procedure, and
the potency of the antithrombotic regimen. Antithrombotic
therapies after coronary intervention reduce ischemic events
but invariably increase bleeding risk, which in turn may
adversely affect short- and long-term outcomes.5,6 Interna-
tional guidelines recommend careful evaluation of both
ischemic and bleeding risk based on the patient’s clinical
characteristics7,8; however, evidence supporting the individ-
ualization of antithrombotic therapy is still limited. In partic-
ular, the potency and duration of dual antiplatelet therapy
(DAPT) after coronary stenting are currently based mainly on
the patient’s clinical presentation (ie, acute coronary syn-
drome or stable coronary artery disease) and the type of stent
used (ie, drug-eluting or bare metal stent), with evanescent
indications based on the patient’s bleeding risk.7–9 Many
bleeding risk scores have been validated for the prediction of
early and late bleeding events, and some have been tested on
large cohorts with acute coronary syndrome, demonstrating
reasonably good performance.10–12 Among them, the CRU-
SADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA [American College of Cardiology/
American Heart Association] Guidelines) score has been
validated in 17 857 patients with non–ST-segment elevation
myocardial infarction (MI), and its predictive capability was
consistent in terms of hemorrhagic risks in patients taking ≥2
antithrombotic medications.10 Our study sought to compare
the predictive performance of the CRUSADE, ACUITY (Acute
Catheterization and Urgent Intervention Triage Strategy), and
HAS-BLED (Hypertension, Abnormal Renal/Liver Function,
Stroke, Bleeding History or Predisposition, Labile INR [inter-
national normalized ratio], Elderly, Drugs/Alcohol Concomi-
tantly) risk scores with respect to major bleeding events in an
all-comer population treated with coronary stent. We also
intended to determine the incidence of major bleeding after
24-month rather than 6-month DAPT in the subgroups of
patients with high and low to intermediate bleeding risk.
Methods
The design and main study ﬁndings for the Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia Study (PRODIGY) were reported previously.5 In
brief, all patients receiving a balanced mixture of stents with
varying anti–intimal hyperplasia potency and including both
ﬁrst- and second-generation drug-eluting stents at 3 Italian
sites were randomly allocated at 30 days to either 6 or
24 months of DAPT. Selection criteria were broad, reﬂecting
routine clinical practice. Randomization to 6- or 24-month
DAPT was performed at 30 days and stratiﬁed by center,
ongoing ST-segment elevation MI, presence of diabetes
mellitus, and need for intervention on at least 1 in-stent
restenotic lesion. The study was conducted in accordance
with the principles of the Declaration of Helsinki. The ethics
committees of the 3 participating centers independently
approved the protocol, and all participants gave written
informed consent.
Treatment Protocol
All patients received aspirin (80–160 mg orally, indeﬁnitely)
and clopidogrel (75 mg/day) according to the following
randomization scheme: either 6 months in the short DAPT
group or 24 months in the prolonged DAPT arm, regardless of
the previously implanted stent type or indication for the
coronary procedure.
Follow-up
All randomized patients returned for study visits at 30 days
and then every 6 months for up to 2 years. During follow-up
visits, patients were examined and assessed for adverse
events and asked about antiplatelet therapy compliance; in
addition, 12-lead ECG recordings were obtained.
Study End Points
The primary objective of this analysis was to compare the
predictive performance of the CRUSADE, ACUITY, and HAS-
BLED bleeding risk scores with respect to major bleeding
events, adjudicated according to Bleeding Academic Research
Consortium (BARC) class 3 or 5, among patients recruited to
the PRODIGY trial. Further sensitivity analysis evaluated the
consistency of the results obtained with the BARC classiﬁca-
tion with other widely accepted bleeding deﬁnitions, including
the Thrombolysis in Myocardial Infarction (TIMI) and Global
Use of Strategies to Open Occluded Arteries (GUSTO) scales.
The CRUSADE, ACUITY, and HAS-BLED bleeding risk scores
were calculated, as reported previously,10–12 taking into
account the following exceptions: For the ACUITY score, given
the exclusive use of unfractionated heparin as an anticoag-
ulant in the PRODIGY trial, the “antithrombotic medication”
variable was set to zero; for the HAS-BLED score, given that
patients with an indication for long-term anticoagulation were
not included in the PRODIGY trial, the “labile INR” variable was
set to zero.
To assess the effect of high bleeding risk status in the 24-
and 6-month DAPT treatment arms, we selected the high-risk
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cutoff value of 40 for the CRUSADE score, as reported
previously.10 The incidence of major bleeding, red blood cell
transfusion, and major adverse cardiac events—a composite
of all-cause death, MI, and cerebrovascular accident—was
appraised in the subgroup of patients with high CRUSADE
scores (HCSs; >40) versus those with low to intermediate
scores (≤40) in the 2 DAPT duration arms. All study end point
deﬁnitions were reported previously,13 conﬁrmed on the basis
of documentation collected at each hospital, and centrally
adjudicated by the clinical events committee, the members of
which were unaware of the patients’ treatment-group
assignments. The time frame of interest for the primary end
point was from randomization (ie, 30 days after index
procedure) to 24 months.
Statistical Analysis
Categorical variables were expressed as frequency (percent-
age), whereas continuous variables were expressed as median
(interquartile range). Continuous variables were compared
between randomized groups using the Wilcoxon rank sum
test, whereas for binary variables, the v2 test was used.
Table 1. Baseline Characteristics
Characteristic Major Bleeding (n=53) No Major Bleeding (n=1893) P Value
Age, y 76.3 (71.3–81.3) 68.9 (59.8–76.1) <0.0001
Female sex 28.3% (15/53) 23.1% (438/1893) 0.38
Body mass index, kg/m2 25.4 (24.0–28.7) 26.6 (24.3–29.4) 0.30
Diabetes 34.0% (18/53) 24.0% (455/1893) 0.09
Insulin dependent 7.5% (4/53) 5.8% (110/1893)
Hypertension 77.4% (41/53) 71.7% (1358/1893) 0.37
Hyperlipidemia 52.8% (28/53) 54.9% (1039/1893) 0.76
Current cigarette use 13.2% (7/53) 24.3% (459/1893) 0.06
Creatinine clearance, mL/min 49.5 (36.3–65.5) 75.7 (57.0–96.5) <0.0001
Prior myocardial infarction 41.5% (22/53) 25.9% (491/1893) 0.01
Prior PCI 24.2% (13/53) 18.3% (343/1893) 0.23
Prior CABG 5.7% (3/53) 11.0% (208/1893) 0.21
LVEF 45.0 (35.75–55.0) 52.0 (45–60.0) 0.001
Clinical presentation
Stable angina pectoris 24.5% (13/53) 25.6% (485/1893) 0.85
Acute coronary syndrome 80.6% (40/53) 74.4% (1408/1893)
Multivessel disease 79.2% (42/53) 69.7% (1319/1893) 0.17
No. of treated lesions 1 (1–2) 1 (1–2) 0.30
≥2 treated lesions 35.8% (19/53) 37.6% (712/1893) 0.76
≥3 treated lesions 7.5% (4/53) 11.5% (218/1893)
Multivessel intervention 24.5% (13/53) 26.9% (509/1893) 0.70
At least 1 complex lesion (type B2 or C)* 66.0% (35/53) 66.0% (1250/1893) 0.99
Total ACC/AHA score† 3 (2–5) 3 (2–5) 0.48
Bleeding risk score
CRUSADE score 38 (24–43) 25 (18–35) <0.0001
ACUITY score 20 (14–28) 15 (9–20) <0.0001
HAS-BLED score 2 (1–2) 1 (1–2) <0.0001
ACC indicates American College of Cardiology; ACUITY, Acute Catheterization and Urgent Intervention Triage Strategy; AHA, American Heart Association; CABG, coronary artery bypass
grafting; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED,
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; LVEF, left ventricular ejection fraction; PCI,
percutaneous coronary intervention.
*According to the ACC/AHA coronary lesion classiﬁcation.
†Type A stenoses were coded as 1 point, type B1 stenoses were coded as 2 points, type B2 stenoses were coded as 3 points, and type C stenoses were coded as 4 points.
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In its original derivation, the CRUSADE score assigned
patients to 5 risk strata (very low risk ≤20, low risk 21–30,
moderate risk 31–40, high risk 41–50, very high risk >50).
The ACUITY score deﬁned 4 risk strata (low risk <10,
moderate risk 10–14, high risk 15–19, very high risk ≥20),
whereas HAS-BLED stratiﬁed patients into 3 risk strata (low
risk <2, intermediate risk 2, high risk >2). For the purpose of
this analysis, patients were categorized into 3 bleeding risk
strata across all scores by jointly considering the very high risk
and high risk (high risk) and low risk and very low risk
categories (low risk) as 1 each. A detailed report of the
components of each score is presented in Table S1.
The predictive value of CRUSADE, ACUITY, and HAS-BLED
scores was assessed in Cox regression models and with
receiver operating characteristics area under the curve (AUC)
and category-free net reclassiﬁcation improvement and
integrated discrimination improvement.14 The calibration of
the models was evaluated using the Hosmer–Lemeshow
goodness-of-ﬁt statistical analysis. Net reclassiﬁcation
improvement and integrated discrimination improvement
were calculated by analyzing the differences in patients’
individual estimated probability of experiencing major bleed-
ing events after the addition of the CRUSADE score result to
the models containing the aforementioned bleeding risk
scores. Net reclassiﬁcation improvement represents the
average weighted improvement in discrimination. Integrated
discrimination improvement considers the change in the
estimated prediction probabilities as a continuous variable
and represents the average improvement in predicted
probability.
Estimation of the cumulative incidence of events was
performed using the Kaplan–Meier method, and events were
compared with the log-rank test. Absolute risk difference with
95% CI was calculated for long-term versus short-term
clopidogrel with the Newcombe–Wilson method without
continuity correction. The Mantel–Haenszel v2 test was used
Figure 1. Distribution of bleeding risk scores and major bleeding events in the PRODIGY population. The Venn diagram (center) shows the
patients included in the high bleeding risk category by each score. The ACUITY score had broader inclusion in the high-risk category, whereas
CRUSADE and HAS-BLED were more restrictive (bottom right corner). Bleeding risk score distribution is presented for CRUSADE (top left
corner), ACUITY (top right corner), and HAS-BLED (bottom left corner), with the number of patients with major bleeding in the high-risk category
(gray section) and in the low- to intermediate-risk category according to 3 bleeding deﬁnitions. ACUITY indicates Acute Catheterization and
Urgent Intervention Triage Strategy; BARC, Bleeding Academic Research Consortium; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open
Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly,
Drugs/Alcohol Concomitantly; PRODIGY, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; TIMI,
Thrombolysis in Myocardial Infarction.
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to assess the evidence of statistical interaction on an additive
scale between randomized DAPT duration and bleeding risk
status, according to CRUSADE. The number needed to treat
for harm (NNTH) was calculated as 1 divided by the absolute
risk difference (ARD). All analyses were performed on the
basis of the intention-to-treat principle with Review Manager
version 5.3 (RevMan; Cochrane Collaboration) and SPSS
version 21.0 (IBM Corp).
Results
In the PRODIGY trial, a total of 1970 patients were randomly
allocated at 30 days postprocedure to receive clopidogrel
therapy for 6 or 24 months. Complete data regarding the 3
bleeding risk scores were available in 1946 patients (98.8%).
The 2-year cumulative risk of major bleeding and need for
red blood cell transfusion was 2.7% and 2.0%, respectively
Table 3. Incidence of TIMI Minor and Major Bleeding Among Bleeding Risk Categories
Events (n/N) Hazard Ratio (95% CI) P Value
All patients 2.1% (42/1946) — —
CRUSADE score
Low (≤30) 1.2% (16/1282) Reference —
Intermediate (31–40) 3.0% (11/357) 2.50 (1.16–5.39) 0.019
High (>40) 4.9% (15/307) 4.20 (2.08–8.51) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.1% (10/475) 2.56 (0.80–8.17) 0.112
High (>14) 2.8% (28/991) 3.47 (1.22–9.89) 0.02
HAS-BLED score
Low (<2) 1.3% (13/977) Reference —
Intermediate (2) 2.8% (26/914) 2.17 (1.11–4.22) 0.023
High (>2) 5.4% (3/55) 4.79 (1.36–16.83) 0.015
Each hazard ratio is considered as compared to the reference low bleeding risk category. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; TIMI, Thrombolysis in Myocardial Infarction.
Table 2. Incidence of Major Bleeding Among Bleeding Risk Categories
Major Bleeding Hazard Ratio (95% CI) P Value
All patients 2.7% (53/1946) — —
CRUSADE score
Low (≤30) 1.4% (18/1282) Reference —
Intermediate (31–40) 4.2% (15/357) 3.10 (1.56–6.15) 0.001
High (>40) 6.5% (20/307) 5.62 (2.99–10.55) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.5% (12/475) 3.08 (0.99–9.54) 0.052
High (>14) 3.7% (37/991) 4.93 (1.76–13.82) 0.002
HAS-BLED score
Low (<2) 1.5% (15/977) Reference —
Intermediate (2) 3.7% (34/914) 2.56 (1.40–4.69) 0.002
High (>2) 7.3% (4/55) 5.45 (1.81–16.43) 0.003
Each hazard ratio is considered as compared with the reference low bleeding risk category. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
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(2.2% and 2.6% for TIMI minor or major and GUSTO moderate
to severe bleeding, respectively). Patients randomized to
24-month DAPT duration, compared with those allocated to
6-month DAPT, experienced a signiﬁcant increase in major
bleeding (3.5% versus 2.0%, P=0.042; NNTH 66.7) and
received blood transfusions more frequently (2.7% versus
1.3%, P=0.041; NNTH 71.4). No bleeding event occurred in
the 24 patients for whom bleeding scores were missing.
The median CRUSADE score was 25 (interquartile range
18–35; meanSD: 26.512.8), whereas the median ACUITY
and HAS-BLED scores were 15 (interquartile range 10–21;
meanSD: 15.87.9) and 1 (interquartile range 1–2;
meanSD: 1.30.7), respectively (Table 1 and Figure 1).
By applying previously validated cutoffs, 307 patients (15.8%)
based on CRUSADE, 991 patients (50.9%) based on ACUITY,
and 55 patients (2.8%) based on HAS-BLED met the threshold
for the high or very high bleeding risk category. Most patients
with HCS also satisﬁed high bleeding risk criteria according to
both HAS-BLED and ACUITY, whereas the vast majority of
patients at high bleeding risk according to ACUITY did not
reach the same risk category for the other 2 scores
(Figure 1).
Table 4. Incidence of GUSTO Moderate and Severe Bleeding Among Bleeding Risk Categories
Events (n/N) Hazard Ratio (95% CI) P Value
All patients 2.6% (52/1946) — —
CRUSADE score
Low (≤30) 1.3% (18/1282) Reference —
Intermediate (31–40) 3.6% (13/357) 2.80 (1.36–5.76) 0.005
High (>40) 6.8% (21/307) 5.58 (2.94–10.58) <0.0001
ACUITY score
Low (<10) 0.8% (4/480) Reference —
Intermediate (10–14) 2.5% (12/475) 3.08 (0.99–9.56) 0.052
High (>14) 3.5% (35/991) 4.35 (1.55–12.24) 0.005
HAS-BLED score
Low (<2) 1.4% (14/977) Reference —
Intermediate (2) 3.4% (31/914) 2.40 (1.28–4.52) 0.006
High (>2) 10.9% (6/55) 9.05 (3.47–23.60) <0.0001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
Table 5. Risk Classiﬁcation of Major Bleeding According to the 3 Bleeding Risk Scores
CRUSADE ACUITY HAS-BLED
CRUSADE vs ACUITY ACUITY vs HAS-BLED CRUSADE vs HAS-BLED
Difference P Value Difference P Value Difference P Value
True-positive rate* 37.7% (20/53) 69.8% (37/53) 7.5% (4/53) 32.1 <0.0001 62.3 <0.0001 30.2 <0.0001
False-positive rate† 15.2% (287/1893) 50.3% (954/
1893)
2.7% (51/1893) 35.1 <0.0001 47.6 <0.0001 12.5 <0.0001
False-negative
rate‡
34.0% (18/53) 7.5% (4/53) 28.3% (15/53) 26.5 <0.0001 20.8 <0.0001 5.7 <0.0001
True-negative rate§ 66.7% (1264/
1893)
25.1% (476/
1893)
50.8% (962/
1893)
41.6 <0.0001 25.7 <0.0001 15.9 <0.0001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly.
*Proportion of events categorized as CRUSADE >40, ACUITY >14, and HAS-BLED>2.
†Proportion of events categorized as CRUSADE >40, ACUITY >14, and HAS-BLED>2.
‡Proportion of events categorized as CRUSADE ≤30, ACUITY <10, and HAS-BLED<2.
§Proportion of events categorized as CRUSADE ≤30, ACUITY <10, and HAS-BLED<2.
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The patients who bled were older, had reduced renal
function and left ventricular ejection fraction, had more
frequent history of MI and diabetes mellitus, and underwent
left main coronary artery intervention more frequently. All 3
bleeding risk scores were signiﬁcantly higher for patients with
hemorrhagic events at follow-up compared with those with-
out, consistently across bleeding deﬁnitions (Table 1).
Predictive Performance of the Bleeding Risk
Scores
The transition from a lower to a higher risk category carried a
signiﬁcant increase in bleeding rates across bleeding risk
scores (Table 2). This result was consistent among all
explored bleeding deﬁnitions (Tables 3 and 4) and in the
6- and 24-month DAPT groups when assessed separately. The
ACUITY score best classiﬁed patients with major bleeding in
the high-risk group (higher sensitivity), but it was also the
least speciﬁc, classifying only 25% of patients without events
to the low-risk group. In contrast, the HAS-BLED score
showed the lowest sensitivity, classifying 7.5% of those who
Figure 2. Calibration plots comparing the expected and observed probabilities of major bleeding. A, CRUSADE score. B, ACUITY score. C,
HAS-BLED score. ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of
Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly.
Table 6. ROC: Predictive Performance of Major Bleeding With
the 3 Risk Scores Used as Continuous Variables and as 3 Risk
Score Categories (Low, Intermediate, and High Risk)
Major Bleeding
AUC (95% CI) P Value
CRUSADE score
Continuous parameter 0.71 (0.64–0.77) <0.0001
3 Categories 0.68 (0.60–0.75) <0.0001
ACUITY score
Continuous parameter 0.68 (0.61–0.75) <0.0001
3 Categories 0.61 (0.55–0.68) 0.004
HAS-BLED score
Continuous parameter 0.63 (0.56–0.70) 0.001
3 Categories 0.62 (0.55–0.70) 0.002
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; AUC,
area under the curve; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA
Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; ROC,
receiver operating characteristics.
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eventually bled as high risk. The CRUSADE score provided
reasonable sensitivity and speciﬁcity, correctly classifying
67% of patients without events in the low-risk category
(Table 5).
At the C statistic analysis, the point estimate of the AUC
for the prediction of major bleeding was similar between the
CRUSADE risk score (AUC 0.71, 95% CI 0.64–0.77) and
ACUITY (AUC 0.68, 95% CI 0.61–0.75) and numerically higher
than HAS-BLED (AUC 0.63, 95% CI 0.56–0.70), as both
continuous and 3-risk categories, although 95% CIs remained
partially overlapping among the 3 bleeding scores (Table 6).
All 3 risk models were well calibrated according to the
Hosmer–Lemershow test for goodness of ﬁt (CRUSADE
P=0.27; ACUITY P=0.33; HAS-BLED P=0.69) (Figure 2). These
observations remained consistent when TIMI and GUSTO
bleeding deﬁnitions were applied (Table 7). CRUSADE, but not
ACUITY, successfully reclassiﬁed the risk of major bleeding
compared with HAS-BLED, with better discriminatory power.
When compared with ACUITY, CRUSADE was not signiﬁcantly
superior on net reclassiﬁcation improvement and integrated
discrimination improvement (Table 8 and Figure 3). These
results were largely consistent across different bleeding
scales (Table 9). In addition, the bleeding risk scores,
especially CRUSADE, showed reasonably good discriminatory
capability for ischemic events, including the composite of
death, MI, or cerebrovascular accident; for MI alone; and for
stent thrombosis alone (Table 10).
CRUSADE Score and DAPT Duration
Bleeding events
Patients meeting the threshold for HCS showed an almost 3-
fold greater rate of major bleeding when treated with 24-
versus 6-month DAPT (9.7% versus 3.7%; ARD 6%; 95% CI
0.4% to 12.3%; P=0.04); patients with low to intermediate
Table 7. ROC: Predictive Performance of TIMI Minor or Major and GUSTO Moderate or Severe Bleeding for the 3 Risk Scores Used
as Continuous Variables and as 3 Risk Score Categories (Low, Intermediate, and High Risk)
TIMI Minor or Major GUSTO Moderate or Severe
AUC (95% CI) P Value AUC (95% CI) P Value
CRUSADE score
Continuous parameter 0.68 (0.60–0.76) <0.0001 0.71 (0.63–0.82) <0.0001
3 Categories 0.65 (0.56–0.74) 0.001 0.68 (0.58–0.79) <0.0001
ACUITY score
Continuous parameter 0.65 (0.57–0.73) 0.001 0.67 (0.58–0.77) <0.0001
3 Categories 0.59 (0.52–0.67) 0.036 0.61 (0.51–0.69) 0.009
HAS-BLED score
Continuous parameter 0.62 (0.53–0.69) 0.010 0.65 (0.55–0.73) <0.0001
3 Categories 0.61 (0.52–0.69) 0.019 0.64 (0.53–0.73) 0.001
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; AUC, area under the curve; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver
Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; ROC, receiver operating characteristics; TIMI, Thrombolysis in Myocardial Infarction.
Table 8. Risk Reclassiﬁcation and Integrated Discriminatory Improvement for Major Bleeding
Bleeding Correctly
Reclassiﬁed, P (n1)
No Bleeding Correctly
Reclassiﬁed, P (n2)
Net Reclassiﬁcation
Improvement† P Value
Integrated Discriminatory
Improvement‡ P Value
CRUSADE vs ACUITY* 0.57 (30) 0.49 (921) 0.12 0.49 0.0015 0.488
ACUITY vs HAS-BLED* 0.49 (26) 0.57 (1076) 0.12 0.40 0.0067 0.069
CRUSADE vs HAS-BLED* 0.62 (33) 0.57 (1087) 0.39 0.005 0.0083 0.021
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly.
*The model considered each bleeding risk score as a reference value for the others.
†The net reclassiﬁcation improvement was deﬁned as (A+B)([1A]+[1B]), in which A is the probability of bleeding correctly reclassiﬁed and B is the probability of no bleeding correctly
reclassiﬁed.
‡The integrated discrimination improvement was deﬁned as
ð
P
i
in bleeders ½pnewð1Þpoldð1Þ Þ
n1 
ð
P
i
in non-bleeders ½pnewð2Þpoldð2Þ Þ
n2 :
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CRUSADE scores did not experience a signiﬁcant increase in
major bleeding when treated with long versus short DAPT
duration (2.4% versus 1.6%; ARD 0.8%; 95% CI 0.6% to 2.2%;
P=0.25) (Figure 4A and Table 11). A quantitative interaction
was noted between bleeding risk and duration of antiplatelet
therapy with respect to major bleeding (Pint=0.05) (Figure 5).
The NNTH to experience major bleeding with prolonged DAPT
in the HCS group was 17 (Figure 6). These ﬁndings remained
Figure 3. Reclassiﬁcation tables. The 3 bleeding risk scores are compared using each score as reference
for the others: The ﬁrst score mentioned is the score to be tested, the second is considered the reference.
The percentage of patients correctly reclassiﬁed by each score is displayed in green, whereas the
percentage of patients not correctly reclassiﬁed is in red. ACUITY indicates Acute Catheterization and
Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; HAS-BLED,
Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR,
Elderly, Drugs/Alcohol Concomitantly.
Table 9. Risk Reclassiﬁcation and Integrated Discriminatory Improvement for TIMI Minor or Major and GUSTO Moderate or Severe
Bleeding
Bleeding Correctly
Reclassiﬁed P (n1)
No Bleeding Correctly
Reclassiﬁed, P (n2)
Net Reclassiﬁcation
Improvement† P Value
Integrated Discriminatory
Improvement ‡ P Value
TIMI Minor or Major
CRUSADE vs ACUITY* 0.55 (23) 0.51 (974) 0.12 0.53 0.0022 0.198
ACUITY vs HAS-BLED* 0.45 (19) 0.55 (1055) 0.012 1.00 0.0031 0.256
CRUSADE vs HAS-BLED* 0.62 (26) 0.56 (1065) 0.37 0.03 0.0053 0.069
GUSTO Moderate or Severe
CRUSADE vs ACUITY* 0.53 (27) 0.55 (1044) 0.16 0.26 0.004 0.11
ACUITY vs HAS-BLED* 0.47 (24) 0.53 (998) 0.004 1.00 0.002 0.62
CRUSADE vs HAS-BLED* 0.59 (30) 0.54 (1029) 0.26 0.066 0.006 0.11
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With
Early Implementation of the ACC/AHA Guidelines; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; TIMI, Thrombolysis in Myocardial Infarction.
*The model considered each bleeding risk score as a reference value for the others.
†The net reclassiﬁcation improvement was deﬁned as (A+B)([1A]+[1B]), in which A is the probability of bleeding correctly reclassiﬁed and B is the probability of no bleeding correctly
reclassiﬁed.
‡The integrated discrimination improvement was deﬁned as
ð
P
i
in bleeders ½pnewð1Þpoldð1Þ Þ
n1 
ð
P
i
in non-bleeders ½pnewð2Þpoldð2Þ Þ
n2 :
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consistent across bleeding scales (Table 11). Patients with
HCS experienced an almost 5-fold increase in red blood cell
transfusion in the 24- versus 6-month DAPT duration arms
(8.3% versus 1.8%; ARD 6.5%; 95% CI 1.6% to 12.3%; P=0.02;
NNTH: 15.4), whereas this did not differ in patients with low
to intermediate CRUSADE score (1.7% versus 1.2%; ARD 0.5%;
95% CI 0.6% to 1.7%; P=0.45) (Figure 4B and Table 11), with
positive interaction testing (Pint=0.01) (Figure 5).
Figure 4. Kaplan–Meier curves during follow-up for hemorrhagic and ischemic events in the high and low to intermediate CRUSADE score
categories after 24- or 6-month DAPT. A, Major bleeding. B, Red blood cell transfusion. C, Major adverse cardiovascular events including death
for all causes, myocardial infarction, and cerebrovascular accident. CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy; HAS-BLED, Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; HR, hazard ratio.
Table 11. Hemorrhagic and Ischemic Outcomes in the High and Low to Intermediate CRUSADE Score Groups After 24- or
6-Month Dual Antiplatelet Therapy
HCS (>40) LICS (≤40)
Pint
24-Month
DAPT (n=144)
6-Month DAPT
(n=163) ARD (95% CI)
P
Value
24-Month
DAPT (n=831)
6-Month DAPT
(n=808) ARD (95% CI)
P
Value
Major Bleeding* 9.7% (14) 3.7% (6) 6% (0.4%, 12.3%) 0.04 2.4% (20) 1.6% (13) 0.8% (0.6%, 2.2%) 0.25 0.05
Red blood cell
transfusion
8.3% (12) 1.8% (3) 6.5% (1.6%, 12.3%) 0.02 1.7% (14) 1.2% (10) 0.5% (0.6%, 1.7%) 0.45 0.01
MACE 28.5% (41) 25.8% (42) 2.7% (7.2%, 12.6%) 0.59 6.7% (56) 6.7% (54) 0.0% (2.5, 2.4%) 0.96 0.58
ACUITY indicates Acute Catheterization and Urgent Intervention Triage Strategy; ARD, absolute risk difference; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy; GUSTO, Global Use of Strategies to Open Occluded Arteries; HAS-
BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly; HCS, high CRUSADE score; int,
interaction; LICS, low to intermediate CRUSADE score; MACE, major adverse cardiovascular events consistent with death from all causes, myocardial infarction, and cerebrovascular
accident; TIMI, Thrombolysis in Myocardial Infarction.
*Results consistent among other bleeding deﬁnitions: TIMI minor or major and HCS (7.6% vs 2.4%; ARD 5.2%; 95% CI 0.2% to 10.9%; P: 0.05) and LICS (1.9% vs 1.4%; ARD 0.5%; 95% CI
0.6% to 1.9%; P=0.37) (Pint=0.02). GUSTO moderate or severe and HCS (9.7% vs 4.3%; ARD 5.4%; 95% CI 0.3% to 11.8%; P=0.08) and LICS (2.2% vs 1.5%; ARD 0.7%; 95% CI 0.6% to
2.1%; P=0.30) (Pint=0.08).
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Ischemic events
The risk of death, MI, or cerebrovascular accident did not
differ in the 24- versus 6-month DAPT groups, both in patients
with HCS (28.5% versus 25.8%; ARD 2.7%; 95% CI 7.2% to
12.6%; P=0.59) and with low to intermediate CRUSADE score
(6.7% versus 6.7%; ARD 0%; 95% CI 2.5% to 2.4%; P=0.96)
(Pint=0.58). (Figure 4C and Table 11) Similarly, when sepa-
rately assessed, the risk of all-cause death, MI, or deﬁnite or
probable stent thrombosis remained homogeneously dis-
tributed between DAPT groups in patients with and without
HCS (Table 12).
Discussion
The main ﬁndings of this study can be summarized as follows.
First, the CRUSADE, HAS-BLED, and ACUITY risk scores
demonstrated reasonably good predictive value with respect
to major bleeding in the PRODIGY all-comer population,
regardless of the bleeding deﬁnition used. Second, bleeding
risk scores also displayed a signiﬁcant capability to predict
ischemic events in terms of major adverse cardiac events, MI,
or stent thrombosis. Third, the CRUSADE risk score, predicted
bleeding signiﬁcantly better than HAS-BLED, with improved
reclassiﬁcation and discrimination performance. Fourth,
patients with HCS treated with 24-month DAPT experienced
a 3-fold higher risk of major bleeding and a 5-fold risk of red
blood cell transfusion compared with 6-month DAPT, without
clear evidence of beneﬁt. The NNTH with an HCS was as low
as 17 for major bleeding and 15 for red blood cell transfusion;
these values were lower than corresponding values in the
unselected patient cohort, suggesting that long-term DAPT
has a narrow therapeutic window and high potential for harm
in this selected patient population with high bleeding risk.
Fifth, conversely, patients not meeting the threshold for the
HCS category—corresponding to as many as 84.2% of the
patients originally included in our study—did not have higher
Figure 5. Hemorrhagic and ischemic outcomes in patients with
high and low to intermediate CRUSADE scores. The forest plot
shows the absolute risk difference and the P value of the
interaction effect for major bleeding, red blood cell transfusion,
and MACE after 24- versus 6-month DAPT in the groups of
patients with high and low to intermediate CRUSADE scores.
CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Imple-
mentation of the ACC/AHA Guidelines; DAPT, dual antiplatelet
therapy; int, interaction; MACE, major adverse cardiovascular
events.
Figure 6. Effects of long- and short-term DAPT on patients with a high CRUSADE score and in the overall
population. The number of patients needed to treat to experience major bleeding or red blood cell
transfusion after 24-month DAPT compared with 6-month treatment is signiﬁcantly lower in the group of
patients with a high CRUSADE score (>40) than in the overall study population. CRUSADE indicates Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA Guidelines; DAPT, dual antiplatelet therapy.
Risk Stratiﬁcation in Long or Short DAPT Costa et al
DOI: 10.1161/JAHA.115.002524 Journal of the American Heart Association 12
 at Universitaetsbibliothek Bern on March 14, 2016http://jaha.ahajournals.org/Downloaded from 
bleeding risk, consistently across bleeding risk scales, if
treated with 24- versus 6-month DAPT duration.
There is consensus currently about the need to choose
intensity and/or duration of potent antithrombotic therapy
after percutaneous coronary intervention through the assess-
ment of actual individual bleeding risk. Nevertheless, it
remains undeﬁned how bleeding risk should be properly
assessed and whether it should truly inﬂuence therapeutic
decisions in clinical practice. The ultimate goal of this
analysis was to select 1 bleeding risk score that could guide
duration of DAPT in clinical practice to maximize beneﬁts
over risks. Among the risk scores explored, we found
CRUSADE to have a better predictive proﬁle for major
bleeding compared with HAS-BLED and a similar proﬁle
compared to ACUITY. This observation is consistent with
some previous studies and with the European Society of
Cardiology guidelines that recommended the CRUSADE
score for bleeding risk stratiﬁcation in non–ST-segment
elevation MI.9,15,16 It might be speculated that the set of
covariates used to predict bleeding risk for the CRUSADE
score better reﬂects the bleeding risk in patients undergoing
stent implantation and subsequent DAPT. Accordingly, we
stratiﬁed the PRODIGY patient population into high versus
nonhigh bleeding risk status based on CRUSADE and
assessed whether a priori bleeding risk could be a treatment
modiﬁer with respect to DAPT duration. We failed to identify
a speciﬁc patient population (eg, those at low or interme-
diate bleeding risk) for which long-term DAPT was associated
with lower rates of ischemic end points compared with a
shortened DAPT regimen. This may reﬂect the null ﬁnding of
the PRODIGY trial with respect to the beneﬁt of long-term
DAPT on death, MI, or stroke. In contrast, our study, which
recruited an all-comer patient population, observed a distinct
increase in bleeding end points in patients treated with 24-
month DAPT. The current stratiﬁed analysis largely expands
on previous ﬁndings by showing that in patients with low to
intermediate risk, prolonging DAPT was not associated with a
signiﬁcant bleeding risk consistently across bleeding scales.
Conversely, we observed bleeding and blood transfusion
hazards associated with long-term DAPT in the selected
cohort of patients with high bleeding risk. Given the
magnitude of this association on both relative and absolute
scales, it may be reasonable to stop DAPT after 6 months in
this selected patient population, given that the risks seem to
largely outweigh the potential beneﬁts. At the same time, in
patients not meeting high bleeding risk criteria according to
the CRUSADE score, bleeding risk appears acceptable and
not different from those undergoing 6-month therapy dura-
tion. This may be the ideal patient population in which to
prolong DAPT for long-term secondary prevention.
The recent DAPT trial6 demonstrated that 30-month DAPT
with clopidogrel or prasugrel resulted in a signiﬁcant
reduction of both stent thrombosis and major adverse
cardiac event rates compared with patients treated with 12-
month DAPT. Importantly, patients were eligible for random-
ization only if they were free of both ischemic and bleeding
events at 12 months. The implementation of the DAPT study
results into practice would imply that clinicians should adopt
a 2-step strategy for deciding whether DAPT should or
should not be prolonged beyond 12 months and that only
patients free from bleeding events may be selected to
continue DAPT. This approach may expose patients already
identiﬁable as potential bleeders to treatment-related side
effects that could be prevented by stopping DAPT earlier.
Current European Society of Cardiology revascularization
guidelines call for a shorter DAPT duration in patients at high
bleeding risk.8 ACC/AHA guidelines state that if the bleeding
risk is greater than the anticipated beneﬁt, a shortened
duration of DAPT should be considered.7 The results of our
study may help standardize risk assessment for bleeding in
Table 12. Other Ischemic Outcomes in the High and Low to Intermediate CRUSADE Score Groups After 24- or 6-Month Dual
Antiplatelet Therapy
HCS (>40) LICS (≤40)
Pint
24-Month
Clopidogrel
(n=144)
6-Month
Clopidogrel
(n=163) ARD (95% CI)
P
Value
24-Month
Clopidogrel
(n=831)
6-Month
Clopidogrel
(n=808) ARD (95% CI)
P
Value
Death
from all
causes
20.1% (29) 20.9% (34) 0.8% (9.6% to 8.4%) 0.87 4.1% (34) 3.7% (30) 0.4% (1.5% to 2.3%) 0.69 0.56
MI 11.1% (16) 10.4%(17) 0.7% (6.3% to 7.9%) 0.86 2.5% (21) 2.8% (23) 0.3% (1.9% to 1.2%) 0.69 0.71
Definite/
probable
ST*
1.4% (2) 1.2% (2) 0.2% (3.1 to 3.8%) 0.90 1.3% (11) 1.6% (13) 0.3% (1.5 to 0.9%) 0.63 0.83
CRUSADE indicates Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; MI, myocardial
infarction; ST, stent thrombosis.
*Deﬁnite or probable ST deﬁned according to the academic research consortium.
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clinical practice and may have implications for tailored DAPT
duration.
Our study has several limitations. First, as a retrospective
analysis, the results provided are hypothesis generating, and a
speciﬁcally designed randomized trial is needed to conﬁrm or
refute our ﬁndings. Second, the scores evaluated in this study
were not validated in an all-comer population and were
designed mostly to predict events in the ﬁrst 30 days after
the index procedure. When assessed individually, all variables
included in each score were independent bleeding predictors.
Third, the outcome of interest for the current analysis was
clinically signiﬁcant major bleeding deﬁned according to the
BARC class 3 or 5 deﬁnition. These events are relatively rare in
modern clinical trials and occurred in only 2.7% of the PRODIGY
population. As such, bigger sample sizes are needed to further
corroborate our ﬁndings. Fourth, CRUSADE, ACUITY, and HAS-
BLED scores were validated using a bleeding deﬁnition that was
different from BARC class 3 or 5, as used in the PRODIGY trial;
however, at sensitivity analysis, the result observed for BARC
were conﬁrmedusing TIMIminor ormajor andGUSTOmoderate
and severe deﬁnitions. Fifth, we did not evaluate the perfor-
mance of other bleeding risk scores apart from those presented
in this analysis; consequently, their incremental value in an all-
comer population should be investigated. Sixth, the bleeding
risk scores were collected only on admission. Considering the
sudden variability of clinical status in this population, the result
of the scores at the moment of randomization or during follow-
up may change over time. Continuous and progressive evalu-
ation of bleeding risk would be ideal but, unfortunately, hardly
feasible.
Conclusions
The CRUSADE, ACUITY, and HAS-BLED bleeding risk scores
displayed reasonable predictive performance in an all-comer
population treated with coronary stenting; among them,
CRUSADE showed the best predictive proﬁle in our dataset.
DAPT for 24 months was associated with a higher risk of major
bleeding in patients at high risk based on the CRUSADE score
but not in those with low or intermediate risk proﬁles. The
CRUSADE score has potential to guide DAPT duration based on
standardization of bleeding risk assessed for each individual
patient.
Disclosures
None.
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Table S1. Bleeding risk score calculation in the PRODIGY trial. 
CRUSADE SCORE (N=1948)  
  
Baseline hematocrit, %  
<31 102 (5.2%) 
31–33.9  131 (6.7%) 
34–36.9  230 (11.8%) 
37–39.9  426 (21.9%) 
≥40 1059 (54.4%) 
Creatinine clearance,* mL/min  
≤15 26 (1.3%) 
>15-30 48 (2.5%) 
>30-60 537 (5.2%) 
>60-90 649 (33.3%) 
>90-120 541 (27.8%) 
>120 180 (9.2%) 
  
Heart rate (bpm)   
≤70 1231 (63.2%) 
71-80 378 (19.4%) 
81-90 212 (10.9%) 
91-100 97 (5.0%) 
101-110 18 (0.9%) 
111-120 5 (0.2%) 
>120 7 (0.3%) 
  
Sex  
Male  1495 (76.7%) 
 2 
Female 453 (23.3%) 
  
Signs of CHF at presentation   
No 1836 (94.2%) 
Yes 112 (5.8%) 
  
Prior vascular disease   
No 1696 (87.1%) 
Yes 252 (12.9%) 
  
Diabetes Mellitus  
No 1475 (75.7%) 
Yes 473 (24.3%) 
  
Systolic blood pressure, mm Hg   
≤90 43 (2.2%) 
91-100 69 (3.5%) 
101-120 225 (11.6%) 
121-180 1472 (75.6%) 
181-200 85 (4.4%) 
>200 54 (2.8%) 
  
  
ACUITY SCORE (N=1970)  
  
Gender  
Male 1517 (77.0%) 
Female  453 (23.0%) 
  
Age  
<50 151 (7.7%)  3 
50-59 336 (17.1%) 
60-69 565 (27.5%) 
70-79 649 (32.9%) 
≥80 269 (13.7%) 
  
Serum Creatinine  
≤1  916 (46.5%) 
1-1.2 565 (28.7%) 
1.2-1.4 224 (11.4%) 
1.4-1.6 136  (6.9%) 
1.6-1.8 41 (2.1%) 
1.8-2.0 25 (1.3%) 
≥2.0 63 (3.2%) 
  
White Blood Cell Count (giga/L)  
<10 1475 (74.9%) 
10-11 275 (14.0%) 
12-13 116 (5.9%) 
14-15 56 (2.8%) 
16-17 30 (1.5%) 
18-19 9 (0.5%) 
≥20 9 (0.5%) 
  
  
Previous Anemia 25 (1.3%) 
  
Clinical Presentation  
STEMI 670 (34.0%) 
NSTEMI 460 (23.4%) 
Normal Biomarkers 840 (42.6%) 
 4 
  
Antithrombotic medication Not Applicable 
  
  
HAS BLED SCORE (N=1968)  
  
Hypertension (sBP >160 mmHg) 1445 (73.4%) 
  
Abnormal renal function (ClCr< 50ml/min)  331 (16.8%) 
  
Abnormal liver function ( 2 (0.1%) 
  
Elderly (Age> 65y) 1215 (61.7%) 
  
Previous Stroke 14 (0.7%) 
  
Previous Bleeding 12 (0.6%) 
  
Labile INR Not Applicable 
  
Use of drugs  0 (0.0%) 
  
Use of alcohol 1 (0.1%) 
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